

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31162A
APPLICATION NO.
10/089,971
APPLICANT
GATLIN ET AL.
FILING DATE
AUGUST 13, 2002

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

RECEIVED
JAN 30 2003
TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<input checked="" type="checkbox"/>	AM	0 749 751 A2	12/27/96	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

<input checked="" type="checkbox"/>	AR	Bloomgarden, Zachary T., "American Diabetes Association Annual Meeting, 1998", Diabetes Care, Vol. 22, No. 2, (1999).
<input checked="" type="checkbox"/>	AS	Perfetti et al., "Novel Therapeutic Strategies for the Treatment of Type 2 Diabetes", Diabetes/Metabolism Reviews, No 14, pp 207-225 (1998).
<input checked="" type="checkbox"/>	AT	Dunning, Beth E., "Nateglinide: a glucose-sensitive insulinotropic agent that is chemically and pharmacologically distinct from the sulfonylureas", S29-S31.

EXAMINER

DATE CONSIDERED

28 MAR 2003

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.